TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products that target B-cell malignancies and autoimmune diseases. The company is built around the innovation and development of novel drugs that have the potential to transform how these diseases are treated. The goal at TG Therapeutics is to enrich the quality of life and improve the survival of patients suffering from these diseases.
Based in New York City and incorporated in 1993, TG Therapeutics uses peptides, bispecific antibodies, and small molecules to stimulate and redirect the patient’s immune cells against cancer and autoimmune diseases. The company's core products are TG-1101 (ublituximab), a novel, glycoengineered monoclonal antibody, and TGR-1202, an orally available PI3K delta inhibitor. Both products are in early stage clinical development for patients with hematologic malignancies.
The company's developmental product pipeline includes innovative immunotherapies designed to treat patients with lymphoma, leukemia, and multiple sclerosis. TG Therapeutics aims to deliver safe and effective treatments to patients who present with underserved medical needs. The company's commitment to advancing novel therapeutics also extends to various partnerships aimed at expanding its portfolio and accelerating the development of its pipeline products.
TG Therapeutics operates under a "patient first" principle, striving to bring novel, convenient, and potentially life-saving therapies to patients who need them the most. By targeting the therapeutic gaps with innovative solutions, it has positioned itself as a dynamic player in the competitive biopharmaceutical industry.
The company's strategic business objectives include leveraging advanced technologies and establishing strategic collaborations for additional drug discovery and development. Over the years, it has consistently demonstrated its commitment to research and development to fulfil its vision of improving the landscape of cancer and autoimmune disease therapeutics.
TG Therapeutics' commitment to improving patient outcomes is a driving force behind their culture of innovation. The development approach they use is designed to expedite regulatory approval timelines and increase patient access to their developments. It is this ambition, coupled with commitment and passion, that drives TG Therapeutics to push boundaries and redefine standards in the biopharmaceutical industry. TG Therapeutics, Inc. (TGTX) is more than just a biopharmaceutical company; it's a community of professionals pursuing the shared goal of making a pronounced difference in the lives of patients.